Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Sionna Therapeutics, Inc.NASDAQ: SION
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow turns positive
Q1 FY2026 investing cash flow was $24.82M, compared with -$141.19M a year earlier. Trailing-twelve-month investing cash flow was $47.27M. Over 3 fiscal years it compounded at +59.5% a year.
Context
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near $24.82M or moves back toward the trailing-twelve-month quarterly average of $11.82M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (118.75M) USD
- Year-over-year change
- +6.4%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (118.75M) | +6.4% |
| FY2024 | 2024-12-31 | (126.91M) | -564.0% |
| FY2023 | 2023-12-31 | 27.35M | +193.5% |
| FY2022 | 2022-12-31 | (29.26M) | — |
Investing Cash Flow vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 investing cash flow of $47.27M is the 8th largest of the 11 companies compared; the peer median is $53.18M.
- Its year-over-year change of +132.8% is the 3rd highest of 11, against a peer median of -17.5%.
- Over three fiscal years its annual growth of +59.5% compares with a peer median of +155.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $297.64M | -2073.6% | — | 111.9% | |
| LTM Sep 2026 | $266.86M | -457.9% | — | — | |
| LTM Jun 2026 | $211.26M | +765.6% | — | — | |
| LTM Mar 2026 | $164.39M | +13986.4% | +277.8% | 821.9% | |
| LTM Sep 2026 | $122.04M | -352.6% | — | 179.8% | |
| LTM Sep 2026 | $84.56M | -147.6% | +32.5% | 75500.0% | |
| LTM Mar 2026 | $47.7M | +109.8% | — | 220.7% | |
| LTM Mar 2026 | $47.27M | +132.8% | +59.5% | — | |
| LTM Jun 2026 | $45.47M | +132.7% | — | — | |
| LTM Mar 2026 | $21.81M | +69.1% | — | 5.1% | |
| LTM Mar 2026 | $1.01M | -104.1% | — | 0.3% | |
| Peer median (excluding SION) | $53.18M | -17.5% | +155.1% | 179.8% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.